Literature DB >> 3049228

A cognitive-educational treatment for hypochondriasis.

A J Barsky1, E Geringer, C A Wool.   

Abstract

Hypochondriasis may be conceptualized as a disorder of perception and cognition, in which somatic sensation is experienced as abnormally intense and is then incorrectly attributed to serious medical disease. We describe a therapy to modulate the hypochondriacal patient's somatic sensations, and to alter his or her cognitive appraisal of them, which focuses on four factors that amplify somatic symptoms: (1) attention and expectation; (2) symptom attribution and appraisal; (3) the context used for interpreting the symptoms; and (4) disturbing affect and dependency needs. This therapy, or selected portions of it, can be employed in clinical work with patients individually and in groups, in consultation work, and in more traditional psychotherapeutic settings.

Entities:  

Mesh:

Year:  1988        PMID: 3049228     DOI: 10.1016/0163-8343(88)90003-5

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  5 in total

Review 1.  The relevance of health anxiety to chronic pain: research findings and recommendations for assessment and treatment.

Authors:  Heather D Hadjistavropoulos; Thomas Hadjistavropoulos
Journal:  Curr Pain Headache Rep       Date:  2003-04

Review 2.  Epidemiology and treatment of hypochondriasis.

Authors:  Mónica Magariños; Uzma Zafar; Kore Nissenson; Carlos Blanco
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Behavioural approaches to anxiety disorders.

Authors:  L M Drummond
Journal:  Postgrad Med J       Date:  1993-03       Impact factor: 2.401

4.  Group cognitive and behavioural treatment for hypochondriasis.

Authors:  R Stern; M Fernandez
Journal:  BMJ       Date:  1991-11-16

5.  Reliability and Validity of the Korean Version of Health Anxiety Questionnaire.

Authors:  Kyu-Sic Hwang; Seung-Ho Jang; Hye-Jin Lee; Sang-Yeol Lee
Journal:  Psychiatry Investig       Date:  2018-10-11       Impact factor: 2.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.